Mus vs Oman: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Mus
98.0%
in 2025
Oman
99.0%
in 2025
Mus rank
1st
Oman rank
1st
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Mus
- Oman
How they compare
Oman currently reports 99.0% against 98.0% in Mus, a difference of 1.0%.
Across all 18 years both countries report, Oman has been ahead every year.
Mus ranks 1st and Oman ranks 1st of 2 regions.
Oman has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Mus | Oman | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 48.0% | 48.0% | Oman |
| 2010s | 28.7% | 98.8% | 70.1% | Oman |
| 2020s | 95.0% | 98.7% | 3.7% | Oman |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Mus or Oman?
- Oman, at 99.0% against 98.0% in Mus as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Mus and Oman?
- 1.0%, with Oman ahead.
- How many years of comparable data are there for Mus and Oman?
- 18 years are reported by both, from 2008 to 2025.
- How do Mus and Oman rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Mus ranks 1st and Oman ranks 1st of 2 regions.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.